California researchers screened some 850 miRNAs to uncover one that inhibits growth in cancer cells with KRAS mutations, which are linked to poor survival.
Under the deal, Horizon's X-Man human discovery cell lines will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna's miRNA mimics.
The release of the data comes on the heels of a publication in Cell showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, which Mirna's CEO said bolsters the company's strategy.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.